To test this, we treated the mutant and control mice with VEGFR inhibitor axitinib, an approved drug for treating renal cell carcinoma that has been studied in the treatment of other cancer types (Motzer et al., 2019), for 4.5 months starting at 1.5 months of age. The gene discussed is KDR; the disease is hereditary clear cell renal cell carcinoma.